Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cutaneous Medicine and Surgery
Published in: Journal of Cutaneous Medicine and Surgery 1/2005

01-12-2005

A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence

Authors: Yves Poulin, Kim A. Papp, Wayne Carey, Wayne Gulliver, Aditya K. Gupta

Published in: Journal of Cutaneous Medicine and Surgery | Special Issue 1/2005

Login to get access

Abstract

Moderate to severe plaque psoriasis has traditionally been treated with agents that have toxicities associated with long-term use. Many patients therefore cannot be treated safely, conveniently or effectively with traditional therapies. Recent phase 3 clinical trials for efalizumab, a biological agent targeted specifically at the T-cell-based pathology of psoriasis, have demonstrated its short- and long-term efficacy and safety for the treatment of psoriasis. This article reviews results from 12-week, six-month, and three-year trials, focusing on the drug’s safety, efficacy, and therapeutic response time, as well as the phenomenon of rebound in non-responding patients. Efalizumab emerges as an important addition to the dermatological pharmacopeia for the long-term treatment of psoriasis.
Footnotes
1
The static Physician’s Global Assessment (sPGA) evaluates disease severity at a single point in time. Values are assigned between 0-6 based on definitions clear, minimal, mild, moderate, severe or very severe, respectively.
 
Literature
1.
Cather JC, Menter A. Efalizumab: Continuous therapy for chronic psoriasis. Expert Opin Biol Ther 2005; 5(3):393–403PubMedCrossRef
2.
Leonardi CL. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin 2004; 22:427–435PubMedCrossRef
3.
4.
Cather JC, Cather JC, Menter A. Modulating T–cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003; 3(2):361–370PubMedCrossRef
5.
Della Croce C, Kwan Wong V, Lebwohl MG. Efalizumab in the treatment of psoriasis. Therapy 2004; 1(2):197–202CrossRef
6.
Shear NH, Langley RG, Ho V. Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg 2005; This supplement
7.
Raptiva® (efalizumab) Canadian Prescribing Information. Serono Canada, Inc. 2005
8.
Papp KA, Toth DP. Safety and efficacy of efalizumab retreatment: Final results from an open-label study in psoriasis. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17–21, 2004; Florence, Italy. Poster #74
9.
10.
Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis. JAMA 2003; 290:3073–3080PubMedCrossRef
11.
Gottlieb AB, Gordon KB, Lebwohl MG, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004; 3(6):614–624PubMed
12.
Gottlieb A, Gordon K, Hamilton T, et al. Maintenance of Efficacy and Safety with Continuous Efalizumab Therapy in Patients with Moderate to Severe Chronic Plaque Psoriasis: Final Phase IIIb Study Results. Presented at the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans; 2005. Poster #4
13.
Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell moderator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004–2013PubMedCrossRef
14.
Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141:31–38PubMedCrossRef
15.
Leonardi CL, Papp KA, Gordon KB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52:425–433PubMedCrossRef
16.
Sterry W, Dubertret L, Papp K, et al. Efalizumab for patients with moderate to severe chronic plaque psoriasis: Results of the international, randomized, controlled phase III Clinical Experience Raptiva (CLEAR) trial. Presented at the 34th Annual ESDR Meeting. September 9–11, 2004. Vienna, Austria. Poster #386
17.
Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50:859–866PubMedCrossRef
18.
Stone S, Papp KA, Caro I, et al. Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17–21, 2004; Florence, Italy. Poster #610.
19.
Menter A, Kardatzke D, Rundle AC et al. Incidence and prevention of rebound upon efalizumab discontinuation. Poster presentation at the 11th International Psoriasis Symposium. June 15–18, 2005; Toronto, Canada
20.
Papp KA, Toth D, Rosolph L. Approaches to discontinuing efalizumab: Results of an open-label study comparing different transitioning therapies. Presented at the 3rd European Academy of Dermatology and Venereology Spring Symposium, Sofia, Bulgaria, May 19–22, 2005. Poster #PDT9
21.
Carey W, Rundle AC, Kwon P, Leonardi CL. Taper regimens in the management of patients discontinuing efalizumab therapy. Presented at the 11th International Psoriasis Symposium. June 14–19, 2004; Toronto, Canada. Poster #29
22.
Papp K. Patient management in psoriasis treatment using efalizumab. J Cutan Med Surg 2005; This supplement
23.
Carey W, Toth DP, Bissonnette R et al. No evidence for increased risk of infection during efalizumab treatment: A review of the clinical data. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17–21, 2004; Florence, Italy. Poster #79
24.
Toth DP, Carey W, Bissonnette R et al. Risk of malignancy during efalizumab treatment: A review of the clinical data. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17–21, 2004; Florence, Italy. Poster #110
Metadata
Title
A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence
Authors
Yves Poulin
Kim A. Papp
Wayne Carey
Wayne Gulliver
Aditya K. Gupta
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
Journal of Cutaneous Medicine and Surgery / Issue Special Issue 1/2005
Print ISSN: 1203-4754
Electronic ISSN: 1615-7109
DOI
https://doi.org/10.1007/s10227-006-0102-2

Other articles of this Special Issue 1/2005

Journal of Cutaneous Medicine and Surgery 1/2005 Go to the issue

OriginalPaper

Efalizumab, a reversible T-cell modulator for psoriasis

OriginalPaper

Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches

OriginalPaper

Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis

OriginalPaper

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis